Our work on precision phenotyping of #DCM using clinical, imaging, genetic and biomarker data ➡️ machine learning➡️ 3 novel phenogroups
@JACCJournals
jacc.org/doi/full/10.10…
@JACCJournals
jacc.org/doi/full/10.10…
✅Phenogroup 1➡️Mild Non Fibrotic
✅Phenogroup 2➡️Pro Fibrotic Metabolic
✅Phenogroup 3➡️Biventricular Impairment
Phenogroups added prognostic value to traditional risk models
🧪IL4RA➡️Novel Prognostic Biomarker
✅Phenogroup 2➡️Pro Fibrotic Metabolic
✅Phenogroup 3➡️Biventricular Impairment
Phenogroups added prognostic value to traditional risk models
🧪IL4RA➡️Novel Prognostic Biomarker
What's the background?
💟 DCM is not a final diagnosis, just a description of a phenotype. Actual disease is v heterogenous
💟 Lots of new HF drugs but not all patients benefit
💟 Need to target new and existing treatments to patient groups most likely to benefit
💟 DCM is not a final diagnosis, just a description of a phenotype. Actual disease is v heterogenous
💟 Lots of new HF drugs but not all patients benefit
💟 Need to target new and existing treatments to patient groups most likely to benefit
Why does this study matter?
💟Understanding DCM in a new way
💟Innovation in combining multidimensional data
💟Simple clinical validation model
💟Steps towards true precision medicine for patients with DCM
💟Identifying a new prognostic biomarker (IL4RA)
💟Understanding DCM in a new way
💟Innovation in combining multidimensional data
💟Simple clinical validation model
💟Steps towards true precision medicine for patients with DCM
💟Identifying a new prognostic biomarker (IL4RA)
Complex, challenging study which was an enormous international team effort 🇬🇧🇺🇸🇳🇱🇸🇬 Not everyone is on twitter (!) but I'm so lucky to work with my mentor Prof Sanjay Prasad and this fab team! @imperialcollege @ImperialNHLI @CVGenomics
• • •
Missing some Tweet in this thread? You can try to
force a refresh
